PlumX Metrics
Embed PlumX Metrics

New drugs for peripheral joint psoriatic arthritis

Drug and Therapeutics Bulletin, ISSN: 0012-6543, Vol: 44, Issue: 1, Page: 1-5
2006
  • 1
    Citations
  • 0
    Usage
  • 53
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    1
    • Citation Indexes
      1
  • Captures
    53

Article Description

Up to 3% of people have psoriasis, and as many as 42% of these have an associated chronic inflammatory arthritis. In up to 20% of such patients, the arthritis progresses to become severe, destructive and deforming. Traditional drug treatments include NSAIDs and disease-modifying anti-rheumatic drugs (DMARDs) used for rheumatoid arthritis. ▼Leflunomide(Arava-Sanofi-Aventis), ▼etanercept(Enbrel-Wyeth) ▼inifliximab (Remicade-Schering-Plough) and ▼adalimumab (Humira-Abbott) are licensed for the treatment of patients with peripheral joint disease in psoriatic arthritis. Here we review drug therapy for such patients, concentrating on the newer agents.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know